Biotech M&A Tracker 2026
Live tracker of biotech/biopharma acquisitions announced in 2026 — target, acquirer, deal value, structure, premium, and a one-line “why it matters.”
The page focuses on control transactions at the company level across public and private biotech/biopharma names. BioBucks updates the tracker as new deals are announced; the daily newsletter adds the read-through on what those deals signal for valuation, risk appetite, and strategic priorities.
Last updated: 06 May 2026
Get 2026 biotech M&A updates as they land (free)
The tracker refreshes regularly — the BioBucks newsletter flags new deals and credible rumors daily (in ~5 mins).
Read by 2,000+ VC, BD&L, and public biotech investors. No spam. Unsubscribe anytime.
2026 biotech M&A market snapshot
- 31 transactions are currently tracked here, spanning both public and private biotech/biopharma targets.
- Largest disclosed deal so far: Organon / Sun Pharma at roughly US$11.75B enterprise value, followed by Arcellx / Gilead at roughly US$7.8B implied equity value and Centessa / Lilly at up to US$7.8B.
- The late-April / early-May tape added a fresh wave of strategic, financial-sponsor, and platform-driven activity, including Sun Pharma / Organon, Lilly / Ajax, Teva / Emalex, Chiesi / KalVista, Ligand / XOMA Royalty, ARCHIMED / Esperion, UCB / Candid, Bayer / Perfuse, and Pathos AI / DeuterOncology.
- The tape still looks selective rather than indiscriminate: buyers are paying for approved products, NDA-ready / late-stage assets, or clear strategic platform fit, while sponsor and royalty-aggregator activity is also starting to appear around public-company value dislocations.
May 2026
DeuterOncology
06-May-2026
Acquirer: Pathos AI
Total deal value: Not disclosed
|
Upfront: Not disclosed
Structure: Acquisition of a majority stake
|
Type: Private
|
1D Premium: N/A
Therapeutic area: Oncology / Precision oncology
|
Stage / lead assets: DO-2, a third-generation MET kinase inhibitor for MET-altered cancers
Why it matters: This is a smaller, undisclosed-value control transaction, but strategically notable because Pathos is positioning it as an AI-sourced clinical oncology acquisition. The read-through is that AI-native developers are starting to use proprietary asset-screening platforms not just to design programs internally, but to identify and buy clinical-stage assets with differentiated early data.
Perfuse Therapeutics
06-May-2026
Acquirer: Bayer
Total deal value: Up to US$2.45B
|
Upfront: US$300M cash
Structure: Acquisition (cash upfront + milestone payments)
|
Type: Private
|
1D Premium: N/A
Therapeutic area: Ophthalmology / Retinal disease
|
Stage / lead assets: PER-001, a Phase 2 small-molecule endothelin receptor antagonist for glaucoma and diabetic retinopathy
Why it matters: Bayer is adding a clinical-stage ophthalmology asset and mechanism that could broaden its eye-care pipeline beyond existing retinal franchises. The read-through is that ophthalmology remains a live M&A lane when the target offers a differentiated biology angle and a plausible path into large, high-burden diseases such as glaucoma and diabetic retinopathy.
Candid Therapeutics
03-May-2026
Acquirer: UCB
Total deal value: Up to US$2.2B
|
Upfront: US$2.0B cash
Structure: Acquisition (cash upfront + up to US$200M milestone payments)
|
Type: Private
|
1D Premium: N/A
Therapeutic area: Immunology / Autoimmune disease
|
Stage / lead assets: Cizutamig and a broader autoimmune T-cell engager platform
Why it matters: UCB is doubling down on immunology with a platform-style acquisition built around T-cell engagers for autoimmune disease. Strategically, the deal reinforces the broader sector push toward immune reset approaches, where oncology-derived modalities are being repurposed for chronic autoimmune indications with potentially deeper and more durable efficacy.
Esperion Therapeutics
01-May-2026
Acquirer: ARCHIMED
Total deal value: Up to approximately US$1.1B equity value
|
Upfront: US$3.16/share in cash
Structure: Cash acquisition + up to US$100M contingent milestone payments
|
Type: Public
|
1D Premium: 58% to prior close
Therapeutic area: Cardiovascular / Lipid management
|
Stage / lead assets: NEXLETOL and NEXLIZET, approved oral non-statin LDL-C lowering therapies
Why it matters: This is a public-to-private commercial-stage cardiovascular takeout rather than a classic discovery-platform deal. The read-through is that financial sponsors are prepared to underwrite commercial execution where public markets have struggled to price specialty-pharma assets, especially when there is an approved product base and clearer operating levers outside the public-company spotlight.
April 2026
KalVista Pharmaceuticals
29-Apr-2026
Acquirer: Chiesi Group
Total deal value: Approximately US$1.9B
|
Upfront: US$27.00/share in cash
Structure: Cash tender offer + second-step merger
|
Type: Public
|
1D Premium: Approximately 40% to prior close / 36% to 30-day VWAP
Therapeutic area: Rare disease / Hereditary angioedema
|
Stage / lead assets: EKTERLY / sebetralstat, an oral on-demand treatment for hereditary angioedema attacks
Why it matters: Chiesi is buying a near-commercial rare-disease asset that could change the HAE treatment paradigm by moving on-demand therapy toward an oral option. The read-through is that strategics will pay meaningful premiums for late-stage / launch-ready rare-disease assets where convenience can drive differentiation and where the buyer can plug the product into an existing rare-disease infrastructure.